(AOF) – Innate Pharma (+3% to 2.23 euros) posts one of the strongest increases in the SRD market after the announcement that several abstracts are selected for the European Society of Medical Oncology (Esmo) 2023 congress, taking place from October 20 to 24, 2023 in Madrid (Spain). Among these abstracts, the Phase 1/2 trial led by Sanofi in hematological cancers with SAR’579/IPH6101 will be the subject of an oral presentation.
The biotech specifies that the presentations as part of the collaboration with AstraZeneca concern IPH5201 in early-stage lung cancers (“Trial in Progress” poster) and monalizumab in head and neck cancers.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.